

Index

- access, to fertility treatment, 137–40
 adenomyosis, 33, 40
 adhesions
 intrauterine, 33–4, 35, 40, 41
 tubal, 31
 adjuvants/add-ons in assisted reproduction, 91
 artificial egg activation with calcium ionophore, 89, 103
 assisted hatching, 86
 background on, 82–3
 commonly used, 83–4
 costs of, 83
 embryo glue, 88
 endometrial receptivity array, 87
 endometrial scratching, 84–5, 86
 GM-CSF-containing culture media, 88
 IMSI, 89, 101–2
 PICSI, 89–90, 101–2
 preimplantation genetic screening, 87, 109–10
 professional and regulatory body stances on, 83
 reproductive immunology
 procedures, 90–1
 sperm DNA tests, 90
 time-lapse imaging, 85–6, 106
 adoption, 138–9
 Age-Specific Fertility Rate (ASFR), 1, 3
 air, laboratory, 96
 alcohol intake, 8–9, 10, 25–6, 46
 American Society for Reproductive Medicine (ASRM), 24
 AMH. *See* anti-mullerian hormone andrology. *See* male factor infertility
 anejaculation, 46–7
 aneuploidy, PGT for, 87, 109–10
 anorgasmia, 47
 anovulatory infertility. *See* ovulation disorders
 antibody testing
 chlamydia, 35
 sperm, 51
 thyroid autoantibodies, 8, 9
 anti-mullerian hormone (AMH), 8
 antioestrogens, 14–15, 118
 antiprogestogens, 29
 antral follicle count, 8
 arcuate uterus, 41
 aromatase inhibitors, 16, 29
 ART. *See* assisted reproduction technology
 AS. *See* Asherman's syndrome
 ASFR. *See* Age-Specific Fertility Rate
 Asherman's syndrome (AS), 33–4, 35, 40, 41
 ASRM. *See* American Society for Reproductive Medicine
 assessment. *See also* infertility assessment
 of donors, surrogates and intended parents, 129–30
 embryo, 105–6, 107
 of fertilisation, 101–2, 103
 for fertility preservation, 116–17
 assisted hatching, 86
 assisted reproduction technology (ART), 68. *See also* adjuvants/add-ons in assisted reproduction; laboratory procedures in assisted reproduction; *specific techniques*
 access to treatment with, 137–40
 decision to stop treatment with, 80–1
 HFEA role in, 80
 male factor infertility treatment options in, 52–3
 techniques used in, 68
 unsuccessful, 80–1
 audits, 164
 autonomy, patient, 136, 137, 140–1, 146
 azoospermia
 assisted reproduction treatment options for, 52–3
 causes of, 45–7
 medical treatment options for, 51–2
 surgical treatment options for, 52
 baby design, 146
 bacterial vaginosis, 8
 bias, 151–2, 153
 bicornuate uterus, 41
 biomarkers, for endometriosis, 27
 biopsy
 embryo, 110–11
 testicular, 51
 blastocyst transfer, 74
 body mass index (BMI), 9, 10
 bromocriptine, 19
 buffers, culture media, 95–6
 cabergoline, 19
 calcium ionophores, 89, 103
 cancer treatment, 113. *See also* fertility preservation
 gonadotoxicity risks of, 113, 114
 mechanisms of fertility damage by, 114–15
 ovarian reserve damage by, 114–15
 pregnancy outcomes after, 120
 testicular damage caused by, 46, 115
 CAT. *See* chlamydia antibody testing
 catheters, for embryo transfer, 73
 CBRS. *See* cross border reproductive services
 CC. *See* clomiphene citrate
 Centre for Evidence Based Medicine (CEBM), 150–1
 CF. *See* cystic fibrosis
 chemical motility enhancers, 98–9
 chemotherapy. *See* cancer treatment
 children
 disclosure of third-party conception to, 128–9
 genetic identity of, 144–5
 interests and welfare of, 80, 129–30, 137–8, 143, 145, 146
 posthumous, 120–1, 141–3
 risks to IVF/ICSI conceived, 79
 chlamydia antibody testing (CAT), 35
Chlamydia trachomatis, 8, 31, 46
 class II cabinets, 94, 95
 cleavage stage embryo transfer, 74
 clinical decision making, 147
 clinical governance, 163
 audits, 164
 external review, 165
 quality inspections, 164
 quality sampling, 164
 quality tours, 164–5
 risk management/risk assessment, 164
 clinical practice guidelines, 153–4
 clomiphene citrate (CC), 14–15, 51–2, 56
 cocaine use, 9
 Cochrane risk of bias tool, 151–2

Index

- COCP. *See* combined oral contraceptive pill
- cohort total fertility rate (CTFR), 1
- combined oral contraceptive pill (COCP), 20, 28, 29, 71
- co-morbidities, double jeopardy risks for patients with, 140–1
- conception, prediction models for, 54–6, 57, 63
- confidentiality, 141
- congenital anomalies, in children conceived by IVF/ICSI, 79
- consequentialism, 138
- controlled ovarian stimulation. *See* ovarian stimulation
- corticosteroids, 90–1
- counselling
- before cross border reproductive treatment, 132, 133
 - for donors, surrogates and partners, 130, 131
 - for fertility preservation, 121
 - HFEA requirement for, 123, 124–5
 - implication discussion in, 126, 130, 131
 - offer of, 125
 - in preparation for treatment, 124
 - types of, 124–5
- critical appraisal, literature, 150–4
- cross border reproductive services (CBRS), 131–2, 133
- cryopreservation. *See also* embryo cryopreservation; oocyte cryopreservation
- ethical dilemmas in, 141–4
 - gonadal tissue, 115, 117–20
 - laboratory procedure for, 108–9
 - ovarian tissue, 117–20
 - sperm, 117, 141–4
 - testicular tissue, 117
- cryostorage, 93, 120
- cryptorchidism, 45
- CTFR. *See* cohort total fertility rate
- culture. *See* embryo culture
- cystectomy, 29
- cystic fibrosis (CF), 46, 48, 50
- Danazol, 28
- data protection, 165
- density centrifugation, buoyant, 97–8
- diabetes, 47–8
- diagnostic laparoscopy. *See* laparoscopy
- diagnostic test accuracy studies, 150
- diet, 25–6
- DNA tests, sperm, 90
- document control system, 160–1
- donors. *See also* third-party reproduction
- assessment of, 129–30
 - disclosure of, 128–9
 - ethical dilemmas involving, 144–6
 - future relationship with, 127–8
 - implication discussion and counselling for, 130, 131
 - selection of, 127–8
- dopamine agonists, 19
- double jeopardy risks, for patients with co-morbidities, 140–1
- dye hydrotubation, 10
- dysmenorrhoea, 24–5, 27
- dyspareunia, 27
- EBM. *See* evidence-based medicine
- ectopic pregnancy, 78
- ED. *See* erectile dysfunction
- EFI. *See* endometriosis fertility index
- egg. *See* oocyte
- egg activation, artificial, 89, 103
 - ejaculation, 43, 46–7, 49
 - ejaculatory ducts, transurethral resection of, 52
 - elective egg freezing, 143–4
 - elective single-embryo transfer (eSET), 108
 - embryo, moral status of, 140
 - embryo biopsy, 110–11
 - embryo cryopreservation
 - ethical dilemmas in, 141–4
 - for fertility preservation, 117–20
 - for IVF, 75–6
 - laboratory procedure for, 108–9 - embryo culture
 - buffer use in, 95–6
 - gas phase of, 103–5
 - in incubators, 96, 103, 104
 - laboratory procedure for, 103–5
 - media for, 88, 105
 - pH of, 103 - embryo glue, 88
 - embryo screening, 146
 - embryo selection
 - conventional assessment for, 105–6, 107
 - laboratory procedure for, 105–6, 107
 - time lapse imaging for, 106 - embryo transfer
 - catheters for, 73
 - cleavage stage or blastocyst transfer, 74
 - double, 108
 - in IVF, 59, 62–3, 73–4
 - laboratory procedure for, 105, 106–8
 - number of embryos transferred in, 74, 106–8
 - technique of, 73–4
 - ultrasound use in, 73
- endocrine disorders. *See also*
- hypothalamic pituitary disorders;
 - ovulation disorders
- female, 13
 - male, 45–6, 51–2
 - thyroid, 8, 9
- endocrine tests, for males, 49, 51
- endometrial polyps, 33, 36, 37, 40
- endometrial receptivity array (ERA), 87
- endometrial scratching, 84, 85, 86
- endometrioma, 24, 26, 29, 36
- endometriosis, 22, 24
- aetiopathogenesis of, 22–4
 - description, distribution and classification of, 24, 25, 26
 - diagnosis of, 26–7, 28
 - direct transplantation theory of, 23
 - economic burden of, 27–8
 - epidemiology and risk factors of, 24–6
 - genetic factors in, 23, 26
 - immunological processes in, 23–4
 - management of infertility associated with, 28–9
 - management of pain associated with, 29
 - organisation of care for, 29–30
 - ovarian endometrioma, 24, 26, 29, 36
 - prevalence of, 22
 - socioeconomic burden and psychosocial impact of, 27–8
 - symptoms and signs of, 26–7, 28
 - uterine abnormalities, 33, 40
- endometriosis fertility index (EFI), 24
- endometrium, luteal phase support of, 75
- environment, laboratory, 93–4
- epidemiology of infertility, 1, 2–3, 4
- epididymis, 48
- equipment, validation and verification of, 162
- ERA. *See* endometrial receptivity array
- erectile dysfunction (ED), 47
- eSET. *See* elective single embryo transfer
- ESGE. *See* European Society of Gynaecological Endoscopy
- ESHRE. *See* European Society of Human Reproduction and Embryology
- ethical dilemmas, 136, 137, 146
- baby design, 146
 - comparison of adoptive parent selection to fertility treatment access, 138–9
 - confidentiality, 141
 - consequentialism approach to, 138
 - double jeopardy risks for patients with co-morbidities, 140–1
 - fairness approach to, 139–40
 - in fertility preservation, 120–1

- in gamete cryopreservation, 141–4
 in gamete donation, 144–6
 moral status of human embryos, 140
 in reproductive medicine versus other branches of medicine, 136–7
 rights-based system approaches to, 139
 welfare of potential people, 137–8, 143, 145, 146
 ethical principles, 136, 137
 ethnicity, endometriosis risk and, 25
 European Society of Gynaecological Endoscopy (ESGE), 33, 34
 European Society of Human Reproduction and Embryology (ESHRE), 33, 34
 European Tissues and Cells Directive (EUTCD), 156
 evidence
 application of, 151–2
 critical appraisal of quality of, 150–2, 153
 overall quality of, 153–4
 evidence-based medicine (EBM), 147, 153
 application of evidence, 151–2
 clinical decision making with, 147
 clinical practice guidelines, 153–4
 critical appraisal of literature, 150–4
 literature searches, 148–50
 structured questions, 147–8
 examination. *See* history and examination
 exercise, 25–6
 external review, 165
 fairness, in access to fertility treatment, 139–40
 fecundability, 1, 3
 fecundity, 1
 female factor infertility. *See also* ovulation disorders; tubal abnormalities/tubal factor infertility; uterine abnormalities/uterine factor infertility
 fertility preservation options for, 117–20
 further tests for, 10
 history and examination for, 5, 6
 preliminary investigations for, 7–8, 9
 fertilisation
 assessment of, 101–2, 103
 laboratory procedures for failed, 102–3
 fertility preservation, 113
 alternatives to, 122
 ethical and legal issues in, 120–1
 indications for, 113–14, 115
 mechanisms of cancer treatment damage and, 114–15
 patient assessment prior to, 116–17
 pregnancy outcomes in cancer survivors, 120
 preventative options for men, 121
 preventative options for women, 121
 storage options for men, 117
 storage options for women, 117–20
 fertility rates, 1, 2–3
 fertility sparing surgery, 121
 fertility treatment access, 137–40
 fibroids, uterine, 31–3, 38–9
 fimbrioplasty, 39
 folic acid supplementation, 3–4, 7
 follicle flushing, 73
 follicle-stimulating hormone (FSH), 13, 49, 51
 for ovarian stimulation, 71–2
 for ovarian stimulation in IVF, 71–2
 replacement in males, 51
 gamete cryopreservation. *See* oocyte cryopreservation; sperm cryopreservation
 gamete donation, 52, 79–80. *See also* third-party reproduction
 donor selection for, 127–8
 ethical dilemmas of, 144–6
 as fertility preservation alternative, 122
 for premature ovarian insufficiency, 20
 gamete intrafallopian transfer (GIFT), 79
 genetic tests. *See also* preimplantation genetic testing
 for male infertility, 49–50
 GIFT. *See* gamete intrafallopian transfer
 glue, embryo, 88
 GM-CSF-containing culture media, 87, 88
 GnRH. *See* gonadotropin-releasing hormone
 GnRHa. *See* gonadotropin-releasing hormone analogues
 gonadal tissue cryopreservation, 115, 117–20
 gonadotoxicity, of cancer treatments, 113, 114
 gonadotropin-releasing hormone (GnRH), 13, 45
 congenital absence of, 19
 for hypogonadotropic hypogonadism, 19–20
 replacement in males, 51
 gonadotrophin releasing hormone (GnRH) agonists
 for fertility preservation, 118
 OHSS prevention and, 77–8
 ovarian suppression with, 121
 for pituitary control in IVF, 70, 71
 gonadotropin-releasing hormone analogues (GnRHa), 28, 29
 gonadotropin-releasing hormone (GnRH) antagonists
 for fertility preservation, 118
 OHSS prevention and, 77–8
 for pituitary control in IVF, 70–1
 gonadotropins
 for endometrioma, 29
 for hypogonadotropic hypogonadism, 19–20
 mild ovarian hyperstimulation using, 56
 OHSS prevention and, 77–8
 for ovarian stimulation in IVF, 71–2
 for ovulation induction in PCOS, 17, 18
 HA. *See* hyaluronic acid
 haematogenous spread, endometriosis, 23
 Halban's theory of endometriosis, 23
 hCG. *See* human chorionic gonadotrophin
 HFEA. *See* Human Fertilisation and Embryology Authority
 history and examination
 female, 5, 6
 male, 5, 7, 47–8
 for tubal and uterine abnormalities, 34, 35
 hMG. *See* human menopausal gonadotrophin
 hormone replacement therapy (HRT), 20, 51–2
 HPV vaccination, 3–4
 HRT. *See* hormone replacement therapy
 HSG. *See* hysterosalpingography
 Hull and Rutherford classification, 31, 32
 human chorionic gonadotropin (hCG)
 for male infertility, 51–2
 OHSS prevention and, 77–8
 for ovarian stimulation in IVF, 71, 72
 ovulation triggered by, 69
 Human Fertilisation and Embryology Act, 120, 137–8, 140, 142, 143
 Human Fertilisation and Embryology Authority (HFEA), 156, 164, 165
 adjunct definition of, 82
 adjuvants/add-on stance of, 83
 Code of Practice of, 74, 80, 123, 124–5, 128–9
 counselling requirements of, 123, 124–5
 patient support requirement of, 123, 124
 role of, 80
 on welfare of children, 80

Index

- human menopausal gonadotrophin (hMG), 71
 human resources, 162–3
 hyaluronic acid (HA), 88
 hyaluronidase, 99
 HyCoSy. *See* hysterosalpingo-contrast-sonography
 hydrosalpinx, 39, 41
 hyperprolactinaemia, 18–19, 49
 hypogonadotropic hypogonadism, 19–20, 45
 hypothalamic–pituitary disorders, 18
 female, 18–20
 male, 45–6, 51–2
 hypothyroidism, 8, 9
 hysterosalpingo-contrast-sonography (HyCoSy), 10, 37
 hysterosalpingography (HSG), 10, 36, 58, 63
 hysteroscopy, 10, 37, 40, 41
- ICSI. *See* intracytoplasmic sperm injection
 immunisation, 3–4, 7
 immunoglobulin therapy, 90–1
 immunological processes, in
 endometriosis, 23–4
 immunomodulators, 90–1
 implantation, 75, 83
 implication discussion, 126, 127, 130, 131
 IMSI. *See* intracytoplasmic morphologically selected sperm injection
 in vitro fertilisation (IVF), 70
 adverse obstetric and perinatal outcomes of, 78–9
 assessment of fertilisation after, 101–2, 103
 burden of, 59
 costs of, 59, 83
 decision to stop treatment with, 80–1
 ectopic pregnancy with, 78
 effectiveness of, 58–9
 embryo cryopreservation for, 75–6
 embryo transfer for, 59, 62–3, 73–4
 for endometrioma, 29
 evidence for, 60–3
 failed fertilisation in, 102–3
 future research and clinical practice for, 63–4
 gonadotropins for, 71–2
 IUI versus, 58–9
 laboratory procedures used in, 73
 luteal phase support for, 75
 multiple pregnancy with, 59, 62–3, 78
 OHSS with, 59, 70–1, 76–8
- oocyte retrieval for, 72–3
 optimal timing of, 61–2
 ovarian response monitoring during, 72
 ovarian stimulation for, 57, 59, 63, 70–2
 in PCOS, 17
 pituitary control for, 70–1
 poor response to, 72
 reasons for failure of, 83
 risks of, 76–9
 risks to children conceived with, 79
 safety of, 59, 62–3, 76–9
 sexual intercourse versus, 60–1
 success rates of, 76, 82
 tubal surgery versus, 39–40
 for unexplained infertility, 56–7, 58–9, 60–3
- incubators, embryo culture, 96, 103, 104
 induction theory of endometriosis, 22
 infertility. *See also specific causes*
 cancer treatments causing, 46, 113, 114–15
 confidentiality and, 141
 diagnosis of, 10–11
 epidemiology of, 1, 2–3, 4
 lifestyle advice for, 8–10
 prognosis of, 11, 54–6, 57, 63
 terms and definitions for, 1–3
 unsuccessful treatment of, 136–7
 infertility assessment, 1, 11–12
 advice for patients, 8–10
 diagnosis, 10–11
 further tests, 10, 49–50, 51
 history and examination, 5, 6, 7, 47–8
 infertility consultation, 5, 6, 7
 preliminary investigations, 5–6, 7–8, 9, 48–9
 primary care role in, 4–5
 prognosis, 11
 specialist centre role in, 5
 infertility counselling. *See* counselling
 infliximab, 90–1
 insemination. *See also* intrauterine insemination
 conventional, 99
 insemination *in vitro*, 96–7. *See also* intracytoplasmic sperm injection
 chemical motility enhancers for, 98–9
 conventional, 99
 semen analysis for, 97
 sperm preparation for, 97–8
 sperm vitality tests for, 98
 insulin sensitising agents, 15–16
- internet, in third-party reproduction, 132, 133
 intracytoplasmic morphologically selected sperm injection (IMSI), 89, 101–2
 intracytoplasmic sperm injection (ICSI), 52–3
 assessment of fertilisation after, 101–2, 103
 dish preparation for, 100
 failed fertilisation in, 102–3
 IMSI compared with, 89, 101–2
 indications for, 99
 laboratory procedure for, 99–102
 micromanipulation workstation for, 100
 oocyte preparation for, 99
 PICSI compared with, 89–90, 101–2
 procedure for, 100–1
 rescue, 102–3
 risks to children conceived with, 79
 techniques refining sperm selection for, 101–2
 for unexplained infertility, 63
 intralipids, 90–1
 intrauterine adhesions, 33–4, 35, 40, 41
 intrauterine insemination (IUI), 52, 68
 complications of, 69
 costs of, 59
 cycle monitoring for, 69
 effectiveness of, 58–9
 evidence for, 60, 61
 indications for, 68–9
 IVF versus, 58–9
 procedure for, 69
 safety of, 59, 69
 sexual intercourse versus, 60, 61
 success rates of, 69
 for unexplained infertility, 56, 58–9, 60, 61, 63
 intrauterine pathology, assessment of, 10
 intravenous immunoglobulin, 90–1
 IUI. *See* intrauterine insemination
 IVF. *See* in vitro fertilisation
- justice, in access to fertility treatment, 139–40
- Kallmann syndrome, 19, 45
 karyotyping, 49–50
 key performance indicators (KPIs), 161–2
 Klinefelter syndrome, 46, 47–8, 49–50
 KPIs. *See* key performance indicators
- laboratory investigations
 for men, 5–6, 7, 10, 48–50, 51
 for women, 7–8, 9, 10

- laboratory procedures in assisted reproduction, 93, 111–12
 assessment of fertilisation, 101–2, 103
 buffer use in culture media for, 95–6
 conventional insemination, 99
 cryopreservation, 108–9
 cryostore for, 93
 embryo culture, 103–5
 embryo selection, 105, 106, 107
 embryo transfer, 105, 106–8
 environment for, 93–4
 for failed fertilisation, 102–3
 ICSI, 99–102
 IVF procedures, 73
 oocyte retrieval, 96
 PGT, 109–11
 semen analysis, 96–7, 98
 sperm preparation, 96–9
 sterile working areas for, 94–5
 witness of, 94
 laminar flow hoods, 94–5
 laparoscopic ovarian drilling (LOD), 16–17
 laparoscopy
 for endometriosis diagnosis, 27
 for endometriosis management, 28–9
 pelvic, 10
 for tubal and uterine abnormality diagnosis, 37
 leiomyomas, uterine, 31–3, 38–9
 letrozole, 16, 56, 118
 LH. *See* luteinising hormone
 libido disorders, 47
 lifestyle
 advice for, 8–10
 endometriosis risk and, 25–6
 interventions for unexplained infertility, 58
 male infertility and, 46
 likelihood ratio, 150
 literature
 critical appraisal of, 150–4
 searches, 148–50
 LOD. *See* laparoscopic ovarian drilling
 long GnRH agonist protocol, 70
 luteal phase support, 75
 luteinising hormone (LH), 13, 69, 71
 lymphatic spread, in endometriosis, 23
 macroprolactin, 18–19
 magnetic resonance imaging (MRI)
 for endometriosis diagnosis, 27
 for male infertility, 51
 for tubal and uterine abnormality diagnosis, 37
 male factor infertility, 43, 53
 assisted reproduction treatment options for, 52–3
 causes of, 45–7
 endocrine tests for, 49, 51
 fertility preservation options for, 117
 genetic tests for, 49–50
 history and examination for, 5, 7, 47–8
 medical treatment options for, 51–2
 post-testicular, 46–7
 pre-testicular, 45–6
 prognosis of, 11
 radiological investigations for, 51
 reproductive tract and physiology, 43, 44, 45
 semen analysis for, 5–6, 7, 48–9
 sperm function tests for, 10, 49, 50
 surgical treatment options for, 52
 testicular, 46
 media, culture, 88, 105
 menstruation, 22, 24–5
 MESA. *See* microsurgical epididymal sperm aspiration procedure
 meta-analysis, 148, 150–2, 153–4
 metaplastic transformation, in endometriosis pathogenesis, 22
 metformin, 15–16, 83
 Meyer's theory of endometriosis, 22
 micromanipulation workstation, 100
 microsurgical epididymal sperm aspiration procedure (MESA), 53
 microTESE, 53
 mild ovarian hyperstimulation. *See* ovarian hyperstimulation
 moral status, of human embryos, 140
 motility enhancers, 98–9
 MRI. *See* magnetic resonance imaging
 multiple pregnancy
 with clomiphene citrate use, 15
 with gonadotropins for ovulation induction, 17
 with IUI, 59, 69
 with IVF, 59, 62–3, 78
 with mild ovarian hyperstimulation, 56
 number of embryos transferred and, 74
 mumps orchitis, 46
 National Institute for Clinical Excellence (NICE)
 embryo transfer guidelines of, 74
 fertility preservation guidelines of, 115–16
 IUI indications outlined by, 68–9
 PCOS treatment guidelines of, 14–15, 16, 18
 natural conception, 54–6, 57, 63
 negative predictive value, 150
 NICE. *See* National Institute for Clinical Excellence
 obesity, 47–8, 58
 observational studies, 149–50
 oestradiol, 72
 oestrogen replacement therapy, 20
 OHSS. *See* ovarian hyperstimulation syndrome
 OI. *See* ovulation induction
 oocyte
 artificial activation of, 89, 103
 assessment of fertilisation of, 101–2, 103
 ICSI preparation of, 99
 retrieval of, 72–3, 96
 oocyte cryopreservation
 ethical dilemmas in, 141–4
 for fertility preservation, 117–20
 laboratory procedure for, 108–9
 social or elective, 143–4
 oocyte donation, 79–80. *See also* third-party reproduction
 ethical dilemmas of, 144–6
 as fertility preservation alternative, 122
 for premature ovarian insufficiency, 20
 organisation of services, 156, 165
 clinical governance of, 163–5
 data protection in, 165
 definitions of quality and success for, 156–7
 document control in, 160–1
 equipment and process validation and verification in, 162
 key performance indicators for, 161–2
 process model use in, 157–8
 quality management practice in, 158–65
 Quality Manager for, 159–60
 quality objectives of, 158–9
 quality policy of, 158
 quality review in, 165
 resource management in, 162–3
 structure of, 160
 OTC. *See* ovarian tissue cryopreservation
 ovarian drilling, 16–17
 ovarian endometrioma, 24, 26, 29, 36
 ovarian failure, 8, 20
 ovarian hyperstimulation syndrome (OHSS)
 clinical features of, 76–7
 during fertility preservation protocols, 118
 with gonadotropins, 17
 with IUI, 59, 69
 with IVF, 59, 70–1, 76–8
 management of, 78
 prevention of, 77–8

Index

- ovarian reserve, 8, 70, 72, 114–15
 ovarian shielding, 121
 ovarian stimulation. *See also* ovarian hyperstimulation syndrome
 in fertility preservation, 118
 FSH dose for, 71–2
 gonadotropins for, 71–2
 IUI with, 56, 57, 59, 63, 68–9
 IVF with, 57, 59, 63, 70–2
 pituitary control for, 70–1
 poor response to, 72
 response monitoring during, 72
 ovarian suppression, 121
 ovarian tissue cryopreservation (OTC), 117–20
 ovarian transposition, 121
 ovulation, laboratory investigations of, 7–8
 ovulation disorders, 20. *See also* polycystic ovary syndrome
 hypothalamic–pituitary disorders, 18–20
 premature ovarian insufficiency, 8, 20
 prognosis of, 11
 WHO classification of, 13
 ovulation induction (OI). *See also* ovarian stimulation
 for hypogonadotropic hypogonadism, 19–20
 for PCOS, 14–17, 18
- parents
 assessment of intended, 129–30
 ethical dilemmas involving donation recipients, 144–6
 in surrogacy cases, 145
 patient counselling. *See* counselling
 patient support, 123, 124. *See also* psychosocial support in third party reproduction
 patient-centred care (PCC), 123
 PCOS. *See* polycystic ovary syndrome
 PCT. *See* post-coital test
 pelvic inflammatory disease (PID), 31
 pelvic pain, 27, 29
 pelvic pathology, assessment of, 10
 pelvic ultrasound examination, 8
 pentoxifylline, 98–9
 percutaneous epididymal sperm aspiration (PESA), 53
 Period Total Fertility Rate (PTFR), 1
 peritoneal endometriosis, 24, 25, 26
 PESA. *See* percutaneous epididymal sperm aspiration
 PGD. *See* preimplantation genetic diagnosis
 PGS. *See* preimplantation genetic screening
 PGT. *See* preimplantation genetic testing
 physical resources, 163
 physiological intracytoplasmic sperm injection (PICSI), 89, 101–2
 PID. *See* pelvic inflammatory disease
 pituitary control
 OHSS prevention and, 77–8
 for ovarian stimulation, 70–1
 pituitary disorders. *See* hypothalamic pituitary disorders
 POI. *See* premature ovarian insufficiency
 polycystic ovary syndrome (PCOS), 13, 14
 aromatase inhibitors for ovulation induction in, 16
 clomiphene citrate for ovulation induction in, 14–15
 gonadotrophins for ovulation induction in, 17, 18
 insulin sensitising agents for ovulation induction in, 15–16
 ovarian drilling for ovulation induction in, 16–17
 polyps, endometrial, 33, 36, 37, 40
 positive predictive value, 150
 post-coital test (PCT), 10
 posthumous children/reproduction, 120–1, 141–3
 prediction models for natural conception
 in evidence-based treatment algorithm for unexplained infertility, 63
 history of, 54–5
 performance of, 55–6, 57
 predictive values, 150
 pregnancy. *See also* multiple pregnancy
 after cancer treatment, 120
 ectopic, 78
 endometriosis risk and, 24–5
 preimplantation genetic diagnosis (PGD), 109–10, 146
 preimplantation genetic screening (PGS), 87, 109–10
 preimplantation genetic testing (PGT)
 for aneuploidy, 87, 109–10
 embryo biopsy for, 110–11
 laboratory procedure for, 109–11
 premature ovarian insufficiency (POI), 8, 20
 preservation, fertility. *See* fertility preservation
 prevalence of infertility, 3, 4
 primary care, infertility assessment in, 4–5
 primary infertility, 3
 PRL. *See* prolactin
 process maps, 161
 process model, organisation of services use of, 157–8
 progesterone, 7–8, 75
 progestogens, 29
 prolactin (PRL), 18–19, 49. *See also* hyperprolactinaemia
 prolactinoma, 18–19
 psychological assessment, 5
 psychosocial impact, of endometriosis, 27–8
 psychosocial support in third party reproduction, 123, 125, 132–4
 assessment of intended parents, donors and surrogates, 129–30
 decision to use third party conception, 126–7
 donor, surrogate and partner implication discussion and counselling, 130, 131
 in donor selection and relationship, 127–8
 HFEA counselling requirements and, 123, 124–5
 HFEA patient support requirements and, 123, 124
 implication discussion, 126, 127, 130, 131
 issues to address in, 126, 127
 patient needs in, 127
 after and beyond treatment, 128–9
 PTFR. *See* Period Total Fertility Rate
 public health responsibilities, 3–4
- QM. *See* Quality Manager
 quality assurance, 156, 157. *See also* quality management/quality management system
 quality control, 157
 quality improvement, 157, 162
 quality inspections, 164
 quality management/quality management system, 156, 157, 165
 clinical governance, 163–5
 components of, 158, 159
 data protection, 165
 document control in, 160–1
 key performance indicators, 161–2
 organisation of services practice of, 158–65
 organisational structure and, 160
 process model for, 157–8
 Quality Manager oversight of, 159–60
 quality objectives, 158–9
 resource management, 162–3
 review of, 165
 validation and verification of equipment and processes, 162
 Quality Manager (QM), 159–60
 quality objectives, 158–9
 quality policy, 158

- quality review, 165
 quality sampling, 164
 quality tours, 164–5
- radiotherapy. *See* cancer treatment
 random start protocols, 118
 randomised trials, 148–9, 151–2
 recombinant human FSH (rFSH), 71
 recombinant human LH (r-LH), 71
 recurrent implantation failure (RIF), 83
 Remicap, 90–1
 reproductive endocrine disorders, 13.
 See also ovulation disorders
 reproductive immunology procedures, 90, 91
 rescue ICSI, 102–3
 resource management, 162–3
 retained products of conception, 41
 retrograde ejaculation, 47, 49
 retrograde menstruation, 22
 rFSH. *See* recombinant human FSH
 RIF. *See* recurrent implantation failure
 rights-based systems of ethics, 139
 risk management/risk assessment, in
 organisation of services, 164
 r-LH. *See* recombinant human LH
 Rotterdam criteria, 13–14
 rubella immunisation, 3–4, 7
- salpingostomy, 39
 Sampson's theory of endometriosis, 22
 SCI. *See* spinal cord injury
 scrotal examination, 48
 secondary infertility, 3
 semen analysis, 5–6, 7, 48–9
 laboratory procedure for, 96–7, 98
 sensitivity, diagnostic tests, 150
 septate uterus, 41
 sequential media, 105
 Sertoli cells, 43, 45
 service delivery. *See* organisation of
 services
 SETs. *See* single embryo transfers
 sexual intercourse
 frequency of, 9–10
 IUI or IVF for unexplained
 infertility versus, 60–1
 sexually transmitted infection (STI),
 3–4, 8, 31, 41, 46, 51
 Sheehan's syndrome, 19
 short GnRH agonist protocol, 70,
 77–8
 single embryo transfers (SETs), 59,
 62–3, 74, 108
 single-step medium, 105
 slow freezing technique,
 108–9
 smoking, 8, 10, 25–6, 46
 social egg freezing, 143–4
- socioeconomic burden, of
 endometriosis, 27–8
 sodium bicarbonate buffer, 96
 SOPs. *See* standard operating
 procedures
 specialist centres, infertility assessment
 in, 5
 specificity, diagnostic tests, 150
 sperm. *See also* azoospermia
 delivery of, 43, 46–7
 motility enhancers for, 98–9
 preparation of, 96–9
 production of, 115, 43, 44, 45
 retrieval of, 120
 surgical recovery of, 53
 sperm antibody testing, 51
 sperm cryopreservation, 117, 141–4
 sperm DNA tests, 90
 sperm donation, 52. *See also* third-
 party reproduction
 ethical dilemmas of, 144–6
 as fertility preservation alternative,
 122
 sperm function tests, 10, 49, 50
 sperm vitality tests, 98
 spermatogenesis, 43, 46, 115
 spinal cord injury (SCI), 46
 SSR. *See* surgical sperm retrieval
 standard operating procedures (SOPs),
 160–1
 Stein–Leventhal syndrome. *See*
 polycystic ovary syndrome
 sterile working areas, 94–5
 steroid therapy, 90–1
 STI. *See* sexually transmitted infection
 storage. *See* cryostorage
 structural uterine abnormalities, 33, 34
 structured questions, 147–8
 subfertility, 2
 surgical sperm retrieval (SSR), 120
 surrogacy, 80
 assessment for, 129–30
 ethical dilemmas of, 145–6
 fertility preservation using, 121
 implication discussion and
 counselling for, 130, 131
 Surrogacy Arrangements Act, 145
 swim-up technique, 97, 98
 synthesis prediction model, 54–6, 57,
 63
 systematic reviews, 148, 150–2, 153–4
- tamoxifen, 15, 118
 TESA. *See* testicular sperm aspiration
 TESE. *See* testicular sperm extraction
 testicular biopsy, 51
 testicular shielding, 121
 testicular sperm aspiration (TESA), 53
 testicular sperm extraction (TESE), 53
 testicular tissue cryopreservation, 117
- testis
 cancer treatment damage to, 46, 115
 causes of infertility involving, 46
 development of, 45
 examination of, 48
 physiology of, 43, 44, 45
 testosterone, 45
 exogenous use of, 45–6
 measurement of, 49, 51
 replacement therapy, 51–2
 TFR. *See* Total Fertility Rate
 theophylline, 98–9
 Third Party Agreements, 163
 third-party reproduction, 123, 132–4.
 See also psychosocial support in
 third party reproduction
 decision to use, 126–7
 ethical dilemmas of, 144–6
 global perspectives on, 131–2, 133
 HFEA Code of Practice in, 123,
 124–5, 128–9
 HFEA counselling requirements in,
 123, 124–5
 HFEA patient support requirement
 in, 123, 124
 internet and medical developments
 impacting, 132, 133
 thromboprophylaxis, for OHSS, 78
 thyroid function screening, 8, 9
 thyroxine replacement therapy, 8, 9
 time-lapse imaging, 85–6, 106
 TNF-alpha blocking agents, 90–1
 Total Fertility Rate (TFR), 1, 2–3
 traceability, 163
 transgender men and women, 114
 transvaginal ultrasonography (TVS)
 for endometriosis diagnosis, 27
 oocyte retrieval using, 72–3
 Trial on Intra-Uterine Insemination
 (TUI) Study, 60
 triple embryo transfer, 108
 tubal abnormalities/tubal factor
 infertility, 31, 41
 assessment of, 10
 causes of, 31, 32
 diagnosis of, 34–8, 39
 history taking for, 34, 35
 investigations for, 34–8, 39
 prevention of, 41
 prognosis of, 11, 31
 treatment for, 38–41
 tubal flushing, 36, 58, 63
 tubal surgery, 39–40
 TUI Study. *See* Trial on Intra-Uterine
 Insemination Study
 TVS. *See* transvaginal ultrasonography
- UAGA. *See* Uniform Anatomical Gift
 Act
 ultrashort protocol, 70

Index

- ultrasound
 - embryo transfer using, 73
 - for endometriosis diagnosis, 27
 - for intrauterine and tubal pathology, 10
 - IUI monitoring with, 69
 - IVF monitoring with, 72
 - for male infertility, 51
 - oocyte retrieval using, 72–3
 - pelvic, 8
 - for tubal and uterine abnormalities, 35–6, 37, 38
- unexplained infertility, 54
 - comparative assessment of IUI versus IVF for, 58–9
 - evidence for IUI for, 60, 61
 - evidence for IVF for, 60–3
 - evidence-based recommendations for, 63
 - first-line therapy of choice for, 58–9
 - future research and clinical practice for, 63–4
 - IUI treatment of, 56, 58–9, 60, 61, 63
 - IVF treatment of, 56–7, 58–9, 60–3
 - lifestyle interventions for, 58
 - prediction models for, 54–6, 57, 63
 - sexual intercourse versus IUI or IVF for, 60–1
 - tubal flushing for, 58, 63
- Uniform Anatomical Gift Act (UAGA), 141–2
- universal medium, 105
- uterine abnormalities/uterine factor infertility, 31, 41
 - adenomyosis, 33, 40
 - assessment of, 10
 - conditions associated with, 31, 32
 - diagnosis of, 34–8, 39
 - endometrial polyps, 33, 36, 37, 40
 - endometriosis in, 33, 40
 - fibroids, 31–3, 38–9
 - history taking for, 34, 35
 - intrauterine adhesions, 33–4, 35, 40, 41
 - investigations for, 34–8, 39
 - prevention of, 41
 - structural, 33, 34
 - treatment for, 38–41
- vaccination, 3–4, 7
- validation
 - of equipment and process, 162
 - of prediction models for natural conception, 55–6
- validity, diagnostic tests, 150
- varicocele, 46, 48, 52
- vasa deferens, 46, 48
- vasectomy, 46, 52
- vasovasostomy, 52
- verification, of equipment and process, 162
- vitrification, 75–6, 108–9, 117–18
- wash and spin, 98
- WHO. *See* World Health Organization
- witness, of laboratory procedures, 94
- World Health Organization (WHO)
 - laboratory reference range for semen characteristics, 6, 7, 49, 98
 - ovulation disorder classification of, 13
 - PCOS treatment guidelines of, 15–16
 - on quality in organisation of services, 156–7
- Y microdeletions, 46, 50
- ZIFT. *See* zygote intrafallopian transfer
- zona pellucida, 86, 110
- zygote intrafallopian transfer (ZIFT), 79